Practicing Cultural Humility to Transform Health Care

Topic: 
Practice Transformation
Publish Date: 
Thursday, June 21, 2018
Moving beyond culture competency to cultural humility acknowledges patients’ authority over their own lived experience

Health care delivery often involves a one-size-fits-all approach. As clinicians, we treat a patient with a particular diagnosis similar to the last patient we saw with the same diagnosis because it’s efficient—we think. But shifting that mindset is one of the best opportunities we have to help people truly thrive. An individual’s lived experience is rich, diverse, and complicated.

Possible Safety Issue with Dolutegravir during Pregnancy: Reports of Neural Tube Defects

Susa Coffey's picture

Submitted by Susa Coffey on Wed, 05/23/2018 - 10:43am

Topic: 
Antiretroviral Therapy
Pharmacologic Topics
Publish Date: 
Wednesday, May 23, 2018

On May 18, 2018, the U.S. Food and Drug Administration and the World Health Organization announced that cases of neural tube defects have been reported in babies of women with HIV who were on treatment with dolutegravir at the time of conception and during early pregnancy. The information comes from an unplanned interim analysis of an observational study (the Tsepamo Study) of ART (dolutegravir/TDF/FTC or efavirenz/TDF/FTC) in pregnant women in Botswana.

Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)

Topic: 
Antiretroviral Therapy
Drug Interactions
Pharmacologic Topics
Step 5: Effective Drug Treatment of HIV
Publish Date: 
Wednesday, April 11, 2018

Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on

Bictegravir/TAF/FTC in Women

Susa Coffey's picture

Submitted by Susa Coffey on Wed, 04/11/2018 - 11:59am

Topic: 
Populations
Publish Date: 
Wednesday, April 11, 2018

The single-pill combination of bictegravir (BIC) with tenofovir alafenamide (TAF) and emtricitabine (FTC), recently approved by the FDA, has been shown in four Phase III trials to be effective as initial therapy

Immediate ART Initiation Improves Time to Viral Suppression

Susa Coffey's picture

Submitted by Susa Coffey on Wed, 04/11/2018 - 11:55am

Topic: 
Step 3: Connecting HIV-Infected People to Quality HIV Care
Publish Date: 
Wednesday, April 11, 2018

The availability of ART immediately after the diagnosis of HIV offers many possible benefits, including earlier engagement in care and earlier HIV suppression, which may result in personal and public health benefits. <--break->Based on randomized clinical trials done in developing-world settings, the World Health Organization now recommends starting ART within 7 days of HIV diagnosis.

Naltrexone Improves Virologic Suppression

Susa Coffey's picture

Submitted by Susa Coffey on Wed, 04/11/2018 - 11:37am

Topic: 
Substance Use / Abuse
Publish Date: 
Wednesday, April 11, 2018

Release from correctional settings is a high-stakes time for persons with HIV, as it is for those with other health issues. People with substance use disorders often relapse, and those with HIV often

Short Bites: Human Papillomavirus (HPV) Update

Topic: 
Oral Health
Publish Date: 
Monday, March 19, 2018

HPV oral and oropharyngeal cancers are more difficult to detect than tobacco-related cancers because the symptoms are not always obvious to an individual, and health professionals may lack the education and background to diagnose HPV-related lesions. Although there are many adjunctive oral cancer screening devices and tests, none of them can currently detect early-stage HPV-positive oral and oropharyngeal cancers. My rule of thumb: Any lesion that persists for 2 weeks should be referred to an oral medicine specialist or oral surgeon to evaluate and biopsy, if indicated.

Pages

Subscribe to Sharespot RSS feed